WRN解旋酶是错配修复缺陷结直肠癌的合成致死靶点
该临床前研究在60个异质性dMMR结直肠癌模型中通过敲除或敲低WRN,发现WRN依赖几乎是普遍特征且可作为患者选择标志物。对靶向治疗、化疗和免疫治疗耐药的模型仍保留WRN依赖,支持WRN作为dMMR/MSI-H结直肠癌尤其是难治患者的治疗靶点。
要点
- WRN依赖在dMMR/MSI-H结直肠癌临床前模型中近乎普遍,可作为患者选择标志物。
- 对靶向治疗、化疗和免疫治疗耐药的模型仍保留WRN依赖。
- WRN靶向可作为dMMR/MSI-H结直肠癌单药或联合治疗策略。
核心结论
- WRN是dMMR/MSI-H结直肠癌的合成致死靶点,在耐药模型中仍具依赖性。
研究设计与样本
- 在60个异质性dMMR结直肠癌临床前模型中进行WRN敲除或敲低。
主要发现
- WRN依赖在60个dMMR结直肠癌临床前模型中几乎是普遍特征。
- 对临床相关靶向治疗、化疗和免疫治疗耐药的模型仍保留WRN依赖。
临床怎么用
- WRN可作为dMMR/MSI-H结直肠癌患者选择的标志物。
- WRN靶向可用于对当前治疗策略难治的dMMR/MSI-H肿瘤。
- WRN靶向可考虑作为单药或与靶向药物、化疗或免疫治疗联合。
局限性
- 证据来自临床前模型,尚未在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer. The clinical effectiveness of targeted therapy and chemotherapy is limited by resistance and drug toxicities, and about half of patients receiving immunotherapy have disease that is refractory to immune checkpoint inhibitors. Loss of Werner syndrome ATP-dependent helicase (WRN) is a synthetic lethality in dMMR/MSI-H cells. To inform the development of WRN as a therapeutic target, we performed WRN knockout or knockdown in 60 heterogeneous dMMR colorectal cancer preclinical models, demonstrating that WRN dependency is an almost universal feature and a robust marker for patient selection. Furthermore, models of resistance to clinically relevant targeted therapy, chemotherapy, and immunotherapy retain WRN dependency. These data show the potential of therapeutically targeting WRN in patients with dMMR/MSI-H colorectal cancer and support WRN as a therapeutic option for patients with dMMR/MSI-H cancers refractory to current treatment strategies. SIGNIFICANCE: We found that a large, diverse set of dMMR/MSI-H colorectal cancer preclinical models, including models of treatment-refractory disease, are WRN-dependent. Our results support WRN as a promising synthetic-lethal target in dMMR/MSI-H colorectal cancer tumors as a monotherapy or in combination with targeted agents, chemotherapy, or immunotherapy.This article is highlighted in the In This Issue feature, p. 1861.
引用
- Picco G, Cattaneo CM, van Vliet EJ, et al. Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Cancer Discov. 2021. PMID: 33837064. doi:10.1158/2159-8290.CD-20-1508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。